Do immune checkpoint inhibitors increase the risk of cardiac events in patients with lung cancer and malignant melanoma?
Patients receiving immune checkpoint inhibitors for lung cancer or melanoma have a higher absolute risk of cardiac events, such as peri-/myocarditis, than previously reported in pharmacovigilance studies.
Among patients with lung cancer and malignant melanoma, ICI treated had increased rates of cardiac events. The absolute risks were higher in these data compared with previous pharmacovigilance studies (e.g. 1.8% peri-/myocarditis 1-year risk).
D’Souza et al. (2020) studied this question.